Literature DB >> 21804190

The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans.

Laurence Menard1, David Saadoun, Isabelle Isnardi, Yen-Shing Ng, Greta Meyers, Christopher Massad, Christina Price, Clara Abraham, Roja Motaghedi, Jane H Buckner, Peter K Gregersen, Eric Meffre.   

Abstract

Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) gene polymorphisms are associated with many autoimmune diseases. The major risk allele encodes an R620W amino acid change that alters B cell receptor (BCR) signaling involved in the regulation of central B cell tolerance. To assess whether this PTPN22 risk allele affects the removal of developing autoreactive B cells, we tested by ELISA the reactivity of recombinant antibodies isolated from single B cells from asymptomatic healthy individuals carrying one or two PTPN22 risk allele(s) encoding the PTPN22 R620W variant. We found that new emigrant/transitional and mature naive B cells from carriers of this PTPN22 risk allele contained high frequencies of autoreactive clones compared with those from non-carriers, revealing defective central and peripheral B cell tolerance checkpoints. Hence, a single PTPN22 risk allele has a dominant effect on altering autoreactive B cell counterselection before any onset of autoimmunity. In addition, gene array experiments analyzing mature naive B cells displaying PTPN22 risk allele(s) revealed that the association strength of PTPN22 for autoimmunity may be due not only to the impaired removal of autoreactive B cells but also to the upregulation of genes such as CD40, TRAF1, and IRF5, which encode proteins that promote B cell activation and have been identified as susceptibility genes associated with autoimmune diseases. These data demonstrate that early B cell tolerance defects in autoimmunity can result from specific polymorphisms and precede the onset of disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21804190      PMCID: PMC3163953          DOI: 10.1172/JCI45790

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling.

Authors:  Adrian F Arechiga; Tania Habib; Yantao He; Xian Zhang; Zhong-Yin Zhang; Andrew Funk; Jane H Buckner
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

2.  Association of PTPN22 gene functional variants with development of pulmonary tuberculosis in Moroccan population.

Authors:  H Lamsyah; B Rueda; L Baassi; R Elaouad; N Bottini; K Sadki; J Martin
Journal:  Tissue Antigens       Date:  2009-06-25

3.  Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation.

Authors:  Hugo Mouquet; Johannes F Scheid; Markus J Zoller; Michelle Krogsgaard; Rene G Ott; Shetha Shukair; Maxim N Artyomov; John Pietzsch; Mark Connors; Florencia Pereyra; Bruce D Walker; David D Ho; Patrick C Wilson; Michael S Seaman; Herman N Eisen; Arup K Chakraborty; Thomas J Hope; Jeffrey V Ravetch; Hedda Wardemann; Michel C Nussenzweig
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962

4.  Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene.

Authors:  Laëtitia Michou; Sandra Lasbleiz; Anne-Christine Rat; Paola Migliorini; Alejandro Balsa; René Westhovens; Pilar Barrera; Helena Alves; Céline Pierlot; Elodie Glikmans; Sophie Garnier; Jean Dausset; Carlos Vaz; Manuela Fernandes; Elisabeth Petit-Teixeira; Isabelle Lemaire; Dora Pascual-Salcedo; Stefano Bombardieri; Jan Dequeker; Timothy R Radstake; Piet Van Riel; Leo van de Putte; Antonio Lopes-Vaz; Bernard Prum; Thomas Bardin; Philippe Dieudé; François Cornélis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-19       Impact factor: 11.205

5.  IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus.

Authors:  Christophe Richez; Kei Yasuda; Ramon G Bonegio; Amanda A Watkins; Tamar Aprahamian; Patricia Busto; Rocco J Richards; Chih Long Liu; Regina Cheung; Paul J Utz; Ann Marshak-Rothstein; Ian R Rifkin
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

6.  Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.

Authors:  Mark D Pescovitz; Carla J Greenbaum; Heidi Krause-Steinrauf; Dorothy J Becker; Stephen E Gitelman; Robin Goland; Peter A Gottlieb; Jennifer B Marks; Paula F McGee; Antoinette M Moran; Philip Raskin; Henry Rodriguez; Desmond A Schatz; Diane Wherrett; Darrell M Wilson; John M Lachin; Jay S Skyler
Journal:  N Engl J Med       Date:  2009-11-26       Impact factor: 91.245

7.  The PTPN22 R620W polymorphism is associated with severe bacterial infections after human leukocyte antigen geno-identical haematopoietic stem-cell transplantations.

Authors:  Mariam Azarian; Marc Busson; Vanderson Rocha; Patricia Ribaud; Regis Peffault de Latour; Hélène Bleux; Virginia Lepage; Dominique Charron; Antoine Toubert; Gérard Socié; Pascale Loiseau
Journal:  Transplantation       Date:  2008-06-27       Impact factor: 4.939

8.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Authors:  Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

Review 9.  Recent advances in the genetics of autoimmune disease.

Authors:  Peter K Gregersen; Lina M Olsson
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

10.  CD40 ligand and MHC class II expression are essential for human peripheral B cell tolerance.

Authors:  Maxime Hervé; Isabelle Isnardi; Yen-shing Ng; James B Bussel; Hans D Ochs; Charlotte Cunningham-Rundles; Eric Meffre
Journal:  J Exp Med       Date:  2007-06-11       Impact factor: 14.307

View more
  150 in total

Review 1.  Polyreactive antibodies in adaptive immune responses to viruses.

Authors:  Hugo Mouquet; Michel C Nussenzweig
Journal:  Cell Mol Life Sci       Date:  2011-11-02       Impact factor: 9.261

2.  Altered BCR signalling quality predisposes to autoimmune disease and a pre-diabetic state.

Authors:  Sebastian Königsberger; Jan Prodöhl; David Stegner; Vanessa Weis; Martin Andreas; Martin Stehling; Theresa Schumacher; Ruben Böhmer; Ina Thielmann; Judith M M van Eeuwijk; Bernhard Nieswandt; Friedemann Kiefer
Journal:  EMBO J       Date:  2012-06-22       Impact factor: 11.598

Review 3.  Genetic susceptibility to lupus: the biological basis of genetic risk found in B cell signaling pathways.

Authors:  Samuel E Vaughn; Leah C Kottyan; Melissa E Munroe; John B Harley
Journal:  J Leukoc Biol       Date:  2012-06-29       Impact factor: 4.962

Review 4.  Protein tyrosine phosphatases and type 1 diabetes: genetic and functional implications of PTPN2 and PTPN22.

Authors:  Karen Cerosaletti; Jane H Buckner
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 5.  Rethinking mechanisms of autoimmune pathogenesis.

Authors:  Shiv Pillai
Journal:  J Autoimmun       Date:  2013-06-25       Impact factor: 7.094

Review 6.  The Contribution of PTPN22 to Rheumatic Disease.

Authors:  Tomas Mustelin; Nunzio Bottini; Stephanie M Stanford
Journal:  Arthritis Rheumatol       Date:  2019-03-02       Impact factor: 10.995

7.  Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.

Authors:  Elizabeth Cotzomi; Panos Stathopoulos; Casey S Lee; Alanna M Ritchie; John N Soltys; Fabien R Delmotte; Tyler Oe; Joel Sng; Ruoyi Jiang; Anthony K Ma; Jason A Vander Heiden; Steven H Kleinstein; Michael Levy; Jeffrey L Bennett; Eric Meffre; Kevin C O'Connor
Journal:  Brain       Date:  2019-06-01       Impact factor: 13.501

8.  Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells.

Authors:  Tuure Kinnunen; Nicolas Chamberlain; Henner Morbach; Jinyoung Choi; Sangtaek Kim; Joseph Craft; Lloyd Mayer; Caterina Cancrini; Laura Passerini; Rosa Bacchetta; Hans D Ochs; Troy R Torgerson; Eric Meffre
Journal:  Blood       Date:  2012-12-05       Impact factor: 22.113

9.  A cryptic polyreactive antibody recognizes distinct clades of HIV-1 glycoprotein 120 by an identical binding mechanism.

Authors:  Jordan D Dimitrov; Cyril Planchais; Tobias Scheel; Delphine Ohayon; Stephane Mesnage; Claudia Berek; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  J Biol Chem       Date:  2014-05-06       Impact factor: 5.157

Review 10.  A functional framework for interpretation of genetic associations in T1D.

Authors:  Gerald T Nepom; Jane H Buckner
Journal:  Curr Opin Immunol       Date:  2012-07-26       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.